{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:06:55Z","timestamp":1784531215401,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Spanish National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009253","name":"EASL International Liver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119741","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:33:14Z","timestamp":1783348394000},"page":"119741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibition of the ZEB1\u2013BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"201","author":[{"given":"Ester","family":"Gonzalez-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7967-7042","authenticated-orcid":false,"given":"Marie","family":"Vallette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4706-7250","authenticated-orcid":false,"given":"Lucia","family":"Garcia-Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-8524","authenticated-orcid":false,"given":"Aashreya","family":"Ravichandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-4643","authenticated-orcid":false,"given":"Mirko","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-8706","authenticated-orcid":false,"given":"Allan","family":"Pavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-7517","authenticated-orcid":false,"given":"Josep","family":"Amengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3015-563X","authenticated-orcid":false,"given":"Carlos Andres","family":"Rold\u00e1n-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Martin","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-4394","authenticated-orcid":false,"given":"Corentin","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-8440","authenticated-orcid":false,"given":"Isabel","family":"Fabregat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Coulouarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-0564","authenticated-orcid":false,"given":"Lynda","family":"Aoudjehane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-5610","authenticated-orcid":false,"given":"Laura","family":"Fouassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-6962","authenticated-orcid":false,"given":"Javier","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119741_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119741_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119741_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119741_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119741_bib5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/HEP.0000000000000206","article-title":"Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma","volume":"79","author":"Cantallops Vila","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119741_bib6","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/hep.32069","article-title":"Zinc finger e-box binding homeobox 1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling","volume":"74","author":"Lobe","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119741_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12672-022-00601-2","article-title":"Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1","volume":"13","author":"Li","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119741_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/odi.14209","article-title":"Epithelial-mesenchymal transition and cancer stem cells: a route to acquired cisplatin resistance through epigenetics in HNSCC","volume":"29","author":"Lima de Oliveira","year":"2023","journal-title":"Oral. Dis."},{"key":"10.1016\/j.biopha.2026.119741_bib9","first-page":"11","article-title":"ROCK2 confers acquired gemcitabine resistance in pancreatic cancer cells by upregulating transcription factor ZEB1","author":"Zhou","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119741_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/01.TP.0000124286.82961.7E","article-title":"Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT","volume":"77","author":"Matsumura","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.biopha.2026.119741_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119741_bib12","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biopha.2026.119741_bib13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.dld.2019.03.019","article-title":"Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma","volume":"51","author":"Angenard","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.biopha.2026.119741_bib14","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/hep.26577","article-title":"Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma","volume":"58","author":"Sulpice","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119741_bib15","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/1078-0432.CCR-17-3725","article-title":"The IGF2\/IR\/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to egfr inhibition in cholangiocarcinoma","volume":"24","author":"Vaquero","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119741_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41388-024-03010-7","article-title":"ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions","volume":"43","author":"Durand","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119741_bib17","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119741_bib18","doi-asserted-by":"crossref","first-page":"D1243","DOI":"10.1093\/nar\/gkae974","article-title":"The UCSC Genome Browser database: 2025 update","volume":"53","author":"Perez","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119741_bib19","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.5210","article-title":"Real-time IncuCyte((R)) Assay for the Dynamic Assessment of Live and Dead Cells in 2D Cultures","volume":"15","author":"Gidda","year":"2025","journal-title":"Bio Protoc."},{"key":"10.1016\/j.biopha.2026.119741_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119741_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189024","article-title":"Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?","volume":"1878","author":"Gielecinska","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119741_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular Bases of Chemoresistance in Cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr. Drug. Targets"},{"key":"10.1016\/j.biopha.2026.119741_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00018-008-8465-8","article-title":"The role of the ZEB family of transcription factors in development and disease","volume":"66","author":"Vandewalle","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2026.119741_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/0008-5472.CAN-17-2476","article-title":"Pleiotropic Roles for ZEB1 in Cancer","volume":"78","author":"Caramel","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119741_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914742","article-title":"Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC","volume":"24","author":"Gohlke","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119741_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.biopha.2026.119741_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70025","article-title":"IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer","volume":"28","author":"Wu","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119741_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41419-018-0808-2","article-title":"Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance","volume":"9","author":"Che","year":"2018","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.biopha.2026.119741_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000493864","article-title":"ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2","volume":"63","author":"Cui","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.biopha.2026.119741_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/cdd.2013.123","article-title":"The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma","volume":"21","author":"Sanchez-Tillo","year":"2014","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.biopha.2026.119741_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell."},{"key":"10.1016\/j.biopha.2026.119741_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/a-2551-0724","article-title":"Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer","volume":"45","author":"Sererols-Vinas","year":"2025","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.biopha.2026.119741_bib33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-12-2130","article-title":"Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma","volume":"73","author":"Mertens","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119741_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41392-025-02347-z","article-title":"NADPH oxidase 1\/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts","volume":"10","author":"Amengual","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119741_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.120029","article-title":"Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma","volume":"1872","author":"Zhu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"10.1016\/j.biopha.2026.119741_bib36","article-title":"CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma","volume":"9","author":"Tsai","year":"2014","journal-title":"PLoS. One"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:48:01Z","timestamp":1784530081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0753332226007778"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119741","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the ZEB1\u2013BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119741"}}